ATLANTA--(BUSINESS WIRE)--MIV Therapeutics, Inc. (OTCBB: MIVT) (Frankfurt: MIV), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announces that the first patients have been enrolled in the registration trial of its VESTAsync™ polymer-free drug-eluting stent. Based on excellent nine-month human safety and efficacy data reported in March at the American College of Cardiology meeting, the Company has accelerated its original timeline for the VESTASYNC II trial, which is designed to test the efficacy of the VESTAsync™ in a sufficient number of patients to form the basis of a regulatory filing for marketing approval in Europe. It is anticipated that these patient data will also be part of an eventual submission to the U.S. Food and Drug Administration.
